{"log_id": 4987540470632476029, "direction": 0, "words_result_num": 38, "words_result": [{"probability": {"variance": 2.2e-05, "average": 0.984434, "min": 0.979762}, "location": {"width": 34, "top": 50, "height": 48, "left": 1168}, "words": "一督"}, {"probability": {"variance": 0.053087, "average": 0.769316, "min": 0.53891}, "location": {"width": 110, "top": 136, "height": 53, "left": 838}, "words": "药珍"}, {"probability": {"variance": 0.004483, "average": 0.893692, "min": 0.826736}, "location": {"width": 32, "top": 109, "height": 71, "left": 1163}, "words": "明缝"}, {"probability": {"variance": 0.010072, "average": 0.960911, "min": 0.483039}, "location": {"width": 773, "top": 195, "height": 31, "left": 255}, "words": "1.5:95%可信区间:0.8-2.9)。在妊娠前3个月内使用帕罗西清和其他抗抑郁药时,心血管"}, {"probability": {"variance": 0.007515, "average": 0.979384, "min": 0.435619}, "location": {"width": 773, "top": 234, "height": 33, "left": 256}, "words": "畸形的发生率分别为1.5%和1。在母亲妊娠前三个月服用了帕罗西汀的12出现心血管畸"}, {"probability": {"variance": 0.00039, "average": 0.989948, "min": 0.916461}, "location": {"width": 768, "top": 274, "height": 33, "left": 257}, "words": "形婴儿中,有9例患有VSDs这项研究还提示,与其他抗抑郁药物相比较,帕罗西汀增加了"}, {"probability": {"variance": 0.010008, "average": 0.963449, "min": 0.504554}, "location": {"width": 773, "top": 315, "height": 31, "left": 256}, "words": "主要先天性畸形的总风险(包括心血管缺陷)(0R:1.8:95%可信区间:112~2.8)。在母"}, {"probability": {"variance": 0.006639, "average": 0.98113, "min": 0.540513}, "location": {"width": 775, "top": 355, "height": 31, "left": 257}, "words": "亲妊娠前3个月使用过帕罗西汀的婴儿中,全部先天性畸形的发生率为4%,连母亲妊娠前3"}, {"probability": {"variance": 0.002216, "average": 0.98723, "min": 0.759856}, "location": {"width": 621, "top": 395, "height": 31, "left": 258}, "words": "个月内使用过其他抗抑郁药物的婴几中,全部先天性畸形的发生率为2%"}, {"probability": {"variance": 0.013066, "average": 0.962104, "min": 0.393374}, "location": {"width": 740, "top": 433, "height": 33, "left": 301}, "words": "动物试验:在器官形成期,给予大鼠50mgkg/日或兔6mg/kg/日剂量的帕罗西汀生殖试"}, {"probability": {"variance": 0.00047, "average": 0.992199, "min": 0.870632}, "location": {"width": 786, "top": 473, "height": 32, "left": 256}, "words": "验中,这些剂量是人体最大推荐剂量(MRHD)的8倍(大鼠)和2倍(兔)。试验中没有发现"}, {"probability": {"variance": 2.9e-05, "average": 0.997248, "min": 0.969018}, "location": {"width": 784, "top": 512, "height": 31, "left": 257}, "words": "致畸作用。但是,当于妊娠期最后三个月给药至哺乳期时,哺乳期前4天仔鼠的死亡数量增"}, {"probability": {"variance": 0.004462, "average": 0.971089, "min": 0.651587}, "location": {"width": 563, "top": 552, "height": 30, "left": 259}, "words": "加。当剂量为1mg/kg/日或者接近1/6的1mg/m人体最大推荐剂量"}, {"probability": {"variance": 0.005657, "average": 0.970986, "min": 0.758338}, "location": {"width": 173, "top": 552, "height": 23, "left": 868}, "words": "D)时,亦可出现这"}, {"probability": {"variance": 9.1e-05, "average": 0.995344, "min": 0.961837}, "location": {"width": 574, "top": 589, "height": 32, "left": 259}, "words": "种作用。没有测定仔鼠死亡的无效剂量。仔鼠的死亡原因也不清楚"}, {"probability": {"variance": 0.004113, "average": 0.97501, "min": 0.690125}, "location": {"width": 732, "top": 627, "height": 32, "left": 303}, "words": "非畸形作用:干妊娠末期三个月内暴露于本品和其他 SSRIS、或5一羟色胺一去甲肾上腺素"}, {"probability": {"variance": 0.002875, "average": 0.984902, "min": 0.758025}, "location": {"width": 778, "top": 666, "height": 33, "left": 257}, "words": "再摄取抑制剂( SARIS)的新生儿,会因出现并发症而需要延长住院时间、延长呼吸支持和"}, {"probability": {"variance": 0.01076, "average": 0.977967, "min": 0.353658}, "location": {"width": 756, "top": 708, "height": 27, "left": 258}, "words": "管饲的时间。这些并发症可于出生后迅速发生已有报告中的临床所见包括有呼吸窘迫"}, {"probability": {"variance": 0.000516, "average": 0.991459, "min": 0.87185}, "location": {"width": 778, "top": 745, "height": 32, "left": 258}, "words": "发绀、呼吸暂停、癫痫发作、体温波动、喂食困难、呕吐、低血糖、肌张力减退、肌张力"}, {"probability": {"variance": 0.013039, "average": 0.959813, "min": 0.350819}, "location": {"width": 774, "top": 784, "height": 33, "left": 263}, "words": "亢进、反射亢进、震颤、发抖、易激和持续哭闹。这些特征都与SRIs和 ISNRIS的直接毒"}, {"probability": {"variance": 6e-06, "average": 0.998481, "min": 0.989339}, "location": {"width": 777, "top": 822, "height": 33, "left": 258}, "words": "性作用相一致,或可能与一种药物的停药综合征相一致。需要注意的是,在某些病例中的"}, {"probability": {"variance": 0.003565, "average": 0.985881, "min": 0.682392}, "location": {"width": 514, "top": 865, "height": 27, "left": 260}, "words": "临床表现是与5-羟色胺综合征相一致的(参见【注意事项】"}, {"probability": {"variance": 0.00205, "average": 0.985942, "min": 0.726411}, "location": {"width": 738, "top": 900, "height": 32, "left": 301}, "words": "在妊娠后期暴露于 SSRIS的新生儿中,发生新生儿持续性肺动脉高压(PPHN的风险增"}, {"probability": {"variance": 0.007087, "average": 0.969019, "min": 0.527325}, "location": {"width": 758, "top": 939, "height": 32, "left": 261}, "words": "加。在一般人群中,每1000例活胎可出现1-2例PPHN,并与新生儿的发病率和死亡率相关联"}, {"probability": {"variance": 0.005992, "average": 0.974771, "min": 0.546079}, "location": {"width": 775, "top": 980, "height": 31, "left": 261}, "words": "在一项回顾性病例对照临床试验中,有377例妇女所生的婴儿在出生时患有PPHN,而836例"}, {"probability": {"variance": 0.005808, "average": 0.974325, "min": 0.613607}, "location": {"width": 776, "top": 1017, "height": 34, "left": 261}, "words": "妇女所生的婴儿出生时健康;与妊娠期没有暴露于抗抑郁药物的婴儿相比较,在妊娠第20"}, {"probability": {"variance": 0.002061, "average": 0.983652, "min": 0.747062}, "location": {"width": 778, "top": 1056, "height": 32, "left": 262}, "words": "周后暴露于 SSRIS的婴儿中发生PPIN的风险几乎高出6倍。目前尚无确定的证据证实妊娠期"}, {"probability": {"variance": 0.012813, "average": 0.959963, "min": 0.474062}, "location": {"width": 779, "top": 1094, "height": 33, "left": 263}, "words": "暴露于SRIs有发生PPHN的风险;而这项试验也是首次对这一潜在风险进行研究,在这项试"}, {"probability": {"variance": 0.00081, "average": 0.991548, "min": 0.83469}, "location": {"width": 778, "top": 1132, "height": 33, "left": 263}, "words": "验中,纳入的暴露于单一种类的 ISSRIS的病例数不足,故不能确定 SSRIS是否都具有相同的"}, {"probability": {"variance": 8.5e-05, "average": 0.99296, "min": 0.975242}, "location": {"width": 123, "top": 1177, "height": 26, "left": 264}, "words": "PPHN风险水平"}, {"probability": {"variance": 0.000178, "average": 0.995322, "min": 0.9235}, "location": {"width": 640, "top": 1211, "height": 31, "left": 304}, "words": "在暴露于帕罗西汀或其他 SSRIS的妊娠患者中,还有发生早产的上市后报告"}, {"probability": {"variance": 0.004219, "average": 0.985421, "min": 0.604007}, "location": {"width": 728, "top": 1248, "height": 34, "left": 306}, "words": "当于妊娠晚期应用帕罗西汀治疗时,医师应当认真考虑潜在的风险和治疗受益。医师"}, {"probability": {"variance": 0.006232, "average": 0.981898, "min": 0.492899}, "location": {"width": 765, "top": 1289, "height": 32, "left": 267}, "words": "还应当注意到,在一项前瞻性纵向研究中,2C1例有重度抑郁症病史的妇女在妊娠初期情"}, {"probability": {"variance": 0.000492, "average": 0.993957, "min": 0.862894}, "location": {"width": 769, "top": 1326, "height": 34, "left": 265}, "words": "绪正常,但是在妊娠期间,与继续进行抗抑郁症治疗的妊娠妇女相比较,停用了抗抑郁药"}, {"probability": {"variance": 1e-06, "average": 0.999357, "min": 0.997006}, "location": {"width": 420, "top": 1367, "height": 33, "left": 265}, "words": "物的妇女更容易出现重度抑郁症复发或病情恶化"}, {"probability": {"variance": 0.000286, "average": 0.98896, "min": 0.944443}, "location": {"width": 203, "top": 1411, "height": 24, "left": 306}, "words": "5.躁狂和双相情感障碍"}, {"probability": {"variance": 0.000194, "average": 0.995424, "min": 0.915832}, "location": {"width": 728, "top": 1444, "height": 33, "left": 308}, "words": "重性抑郁发作可能是双相情感障碍的最初表现,一般认为(尽管未被对照试验所证实"}, {"probability": {"variance": 9e-06, "average": 0.998685, "min": 0.982947}, "location": {"width": 780, "top": 1483, "height": 33, "left": 269}, "words": "单用抗抑郁药物治疗这样的重性抑郁发作在有双相情感障碍危险的患者中可能会增加其混"}], "language": 3}